Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SERA PROGNOSTICS, INC.SERA · Entity 304 | VP, Clinical Sciences | August 26, 2021 | September 09, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SERA PROGNOSTICS, INC.
Report date August 26, 2021 · Filed September 09, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.95 · Expires 2031-08-26 | Direct | 10,000 |
Reported balance
After 2021-08-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-08-26 · Grant · Acquired 10,000 · Balance 10,000 F1: 1/48th of the shares subject to this option will vest monthly beginning on September 26, 2021, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/48th of the shares subject to this option will vest monthly beginning on September 26, 2021, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 26, 2021 Filed Sep 9, 2021 21:49 UTC | SERA PROGNOSTICS, INC. SERA · Entity 304 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.95 | $0.00 |
DisclosureSEC source: 0001104659-21-114276 · tm2127290-1_4seq1.xml · derivative · entry 1 Garite Thomas · CIK 0001871486 · VP, Clinical Sciences 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Class A Common Stock · 10,000 shares Expires 2031-08-26 F1 · derivative.exercise_date: 1/48th of the shares subject to this option will vest monthly beginning on September 26, 2021, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.